Global Chronic Plaque Psoriasis Market Projected to Grow at 6.9% CAGR, Reaching $29.09 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Chronic Plaque Psoriasis Industry Market Size Be by 2025?
The overall valuation of the chronic plaque psoriasis market has experienced significant upward momentum lately; specifically, projections indicate an expansion from $20.79 billion in 2024 to reach $22.26 billion by 2025, reflecting a consistent year-over-year growth rate of 7.0%. Drivers behind this expansion observed during the prior period encompass several factors, such as an escalating frequency of psoriasis cases, a concurrent increase in associated health conditions, the implementation of supportive insurance coverage mandates, amplified rates of substance use including alcohol and tobacco, and the progressive adoption of remote healthcare services like telemedicine.

What's the Long-Term Growth Forecast for the Chronic Plaque Psoriasis Market Size Through 2029?
The market for chronic plaque psoriasis is projected to exhibit robust expansion over the forthcoming years, achieving a valuation of $29.09 billion by 2029, driven by a compound annual growth rate (CAGR) of 6.9%; this upward trajectory during the projection span is attributable to factors such as the fluctuating global incidence of CPP, a rise in autoimmune disorders, expanding healthcare expenditures, the demographic shift toward an older populace, and a heightened need for successful therapeutic options. Key developments anticipated in this period encompass progress in biologic therapies, the emergence of oral small molecule inhibitors, greater incorporation of digital health solutions, the rise of personalized treatment strategies, and the introduction of biosimilars.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

What Are the Key Growth Drivers Fueling the Chronic Plaque Psoriasis Market Expansion?
Spiraling instances of compromised immune function are anticipated to fuel the expansion of the chronic plaque psoriasis market in the future. Immune system dysfunction describes a condition wherein the body's defense mechanisms operate inadequately, raising vulnerability to illnesses, conditions where the body attacks itself, and malignancies. This rise in immune system failures is credited to various elements, including inherited tendencies, external stimuli, insufficient nutrition, persistent psychological strain, and the growing frequency of autoimmune disorders and contagious diseases such as HIV. Therapy for chronic plaque psoriasis becomes necessary to manage this immune system malfunction, because the body's defenses mistakenly instigate an excessive proliferation of skin cells, resulting in irritation and the development of characteristic lesions. To illustrate the scope, in December of 2022, over eight million residents of the United States were identified as suffering from psoriasis, according to the National Psoriasis Foundation, an American non-profit entity. On a global scale, this ailment affects 125 million individuals, representing approximately 2% to 3% of the worldwide populace, hence, the proliferation of immune system dysfunction serves as a catalyst for the expansion of the chronic plaque psoriasis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

What Are the Key Trends Driving Chronic Plaque Psoriasis Market Growth?
Leading enterprises within the chronic plaque psoriasis sector are dedicating efforts toward creating novel therapeutic agents, particularly those inhibiting IL-17A and IL-17F, aiming to secure a competitive edge in managing this condition. These IL-17A and IL-17F inhibitors represent specialized biologic interventions designed to obstruct interleukin-17A and interleukin-17F, which are crucial pro-inflammatory signaling molecules in the immune cascade, thereby mitigating the inflammatory burden characteristic of autoimmune disorders like chronic plaque psoriasis. Demonstrating this progression, UCB S.A., a biopharmaceutical firm headquartered in Belgium, revealed in October 2023 that the United States Food and Drug Administration granted authorization for BIMZELX (bimekizumab-bkzx) to treat adults suffering from moderate to severe plaque psoriasis candidates for systemic treatment or light therapy. Bimekizumab stands out as the inaugural approved psoriasis treatment engineered specifically to intercept and block both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two pivotal cytokines driving inflammatory reactions. This regulatory green light followed positive outcomes derived from three large-scale, international Phase 3 studies-identified as BE READY, BE VIVID, and BE SURE-which together evaluated the agent's effectiveness and safety profile across a patient cohort numbering 1,480 individuals afflicted with moderate to severe plaque psoriasis.

How Is the Chronic Plaque Psoriasis Market Segmented?
The chronic plaque psoriasismarket covered in this report is segmented -

1) By Drug Class: Biologics; Small Molecule Drugs
2) By Route Of Administration: Injectable; Oral; Topical
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

Subsegments:
1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22); T-Cell Inhibitors; Others
2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors; Janus Kinase (JAK) Inhibitors; Retinoids; Others

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

Which Companies Are Leading the Charge in Chronic Plaque Psoriasis Market Innovation?
Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy's Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

Which Regions Are Leading the Global Chronic Plaque Psoriasis Market in Revenue?
North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.